BRPI0914091A2 - "igg variante, composição farmacêutica, kit, método para tratar em tumor, método para inibir atividade de vegf, método para modular permeabilidade vascular e método para inibir ou evitar crescimento de células de câncer" - Google Patents

"igg variante, composição farmacêutica, kit, método para tratar em tumor, método para inibir atividade de vegf, método para modular permeabilidade vascular e método para inibir ou evitar crescimento de células de câncer"

Info

Publication number: BRPI0914091A2
Authority: BR; Brazil
Prior art keywords: inhibiting; kit; pharmaceutical composition; cancer cell; cell growth
Prior art date: 2008-10-14

Application number

BRPI0914091A

Other languages

English (en)

Inventor

Henry B Lowman

Lisa A Damico

Napoleone Ferrara

Yik Andy Yeung

Yu-Ju G Meng

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-14

Filing date

2009-10-13

Publication date

2016-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914091(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-13 Application filed by Genentech Inc filed Critical Genentech Inc

2016-09-27 Publication of BRPI0914091A2 publication Critical patent/BRPI0914091A2/pt

2022-05-10 Publication of BRPI0914091B1 publication Critical patent/BRPI0914091B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0914091-3A 2008-10-14 2009-10-13 Igg variante, composição farmacêutica, kit e usos de um igg variante BRPI0914091B1 (pt)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US10508608P	2008-10-14	2008-10-14
US61/105,086		2008-10-14
US15213109P	2009-02-12	2009-02-12
US61/152,131		2009-02-12
US17176809P	2009-04-22	2009-04-22
US61/171,768		2009-04-22
US22051409P	2009-06-25	2009-06-25
US61/220,514		2009-06-25
PCT/US2009/060443 WO2010045193A1 (en)	2008-10-14	2009-10-13	Immunoglobulin variants and uses thereof

Publications (2)

Publication Number	Publication Date
BRPI0914091A2 true BRPI0914091A2 (pt)	2016-09-27
BRPI0914091B1 BRPI0914091B1 (pt)	2022-05-10

Family

ID=41571534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0914091-3A BRPI0914091B1 (pt)	2008-10-14	2009-10-13	Igg variante, composição farmacêutica, kit e usos de um igg variante

Country Status (21)

Country	Link
US (3)	US20100098730A1 (pt)
EP (2)	EP2352521B1 (pt)
JP (2)	JP5913980B2 (pt)
KR (3)	KR101834999B1 (pt)
CN (3)	CN110317272A (pt)
AR (1)	AR073829A1 (pt)
AU (1)	AU2009303526B2 (pt)
BR (1)	BRPI0914091B1 (pt)
CA (1)	CA2739429C (pt)
CL (1)	CL2015000148A1 (pt)
ES (1)	ES2828721T3 (pt)
IL (2)	IL212048B (pt)
MX (1)	MX2011004001A (pt)
PE (2)	PE20150682A1 (pt)
PH (1)	PH12016500081A1 (pt)
PL (1)	PL2352521T3 (pt)
RU (1)	RU2536937C2 (pt)
SG (2)	SG10201605250SA (pt)
TW (2)	TWI572359B (pt)
WO (1)	WO2010045193A1 (pt)
ZA (1)	ZA201102413B (pt)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
HUP0600342A3 (en) *	2001-10-25	2011-03-28	Genentech Inc	Glycoprotein compositions
AU2005304624B2 (en)	2004-11-12	2010-10-07	Xencor, Inc.	Fc variants with altered binding to FcRn
DK2006381T3 (en)	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
US20080127996A1 (en) *	2006-12-04	2008-06-05	Weinhold Dennis G	Method and apparatus to remediate an acid and/or liquid spill
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
ES2566957T3 (es)	2007-09-26	2016-04-18	Chugai Seiyaku Kabushiki Kaisha	Región constante de anticuerpo modificado
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
UA121453C2 (uk)	2008-04-11	2020-06-10	Чугей Сейяку Кабусікі Кайся	Спосіб одержання фармацевтичної композиції, яка містить антитіло
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
EP2233500A1 (en) *	2009-03-20	2010-09-29	LFB Biotechnologies	Optimized Fc variants
JP5616428B2 (ja)	2009-04-07	2014-10-29	ロシュグリクアートアクチェンゲゼルシャフト	三価の二重特異性抗体
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
CA2781519A1 (en)	2009-09-16	2011-03-24	Genentech, Inc.	Coiled coil and/or tether containing protein complexes and uses thereof
EP2516465B1 (en)	2009-12-23	2016-05-18	F.Hoffmann-La Roche Ag	Anti-bv8 antibodies and uses thereof
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
TWI667257B (zh) *	2010-03-30	2019-08-01	中外製藥股份有限公司	促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
TW201742925A (zh)	2010-04-23	2017-12-16	建南德克公司	異多聚體蛋白質之製造
EP2609111B1 (en)	2010-08-24	2017-11-01	F. Hoffmann-La Roche AG	Bispecific antibodies comprising a disulfide stabilized-fv fragment
KR102385507B1 (ko)	2010-11-30	2022-04-12	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
JP5766296B2 (ja)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
CA2827923C (en)	2011-02-25	2021-11-23	Chugai Seiyaku Kabushiki Kaisha	Fc.gamma.riib-specific fc antibody
WO2012116927A1 (en)	2011-02-28	2012-09-07	F. Hoffmann-La Roche Ag	Monovalent antigen binding proteins
MX341921B (es)	2011-02-28	2016-09-07	Hoffmann La Roche	Proteinas de union a antigeno.
KR101614195B1 (ko)	2011-03-29	2016-04-20	로슈 글리카트 아게	항체 Fc 변이체
RU2641256C2 (ru)	2011-06-30	2018-01-16	Чугаи Сейяку Кабусики Кайся	Гетеродимеризованный полипептид
IL282122B2 (en) *	2011-07-06	2025-10-01	Genmab Bv	Antibody variants and their uses
UA117901C2 (uk) *	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
TWI681970B (zh) *	2011-09-30	2020-01-11	日商中外製藥股份有限公司	包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
EP2762166B1 (en)	2011-09-30	2019-09-18	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecules for promoting elimination of antigens
JP6322411B2 (ja)	2011-09-30	2018-05-09	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) *	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013051294A1 (ja)	2011-10-05	2013-04-11	中外製薬株式会社	糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
AU2012323316B2 (en)	2011-10-11	2017-08-10	Viela Bio, Inc.	CD40L-specific Tn3-derived scaffolds and methods of use thereof
SG10201609301QA (en)	2011-11-30	2016-12-29	Chugai Pharmaceutical Co Ltd	Drug containing carrier into cell for forming immune complex
KR102041412B1 (ko) *	2011-12-30	2019-11-11	한미사이언스 주식회사	면역글로불린 Ｆｃ 단편 유도체
SG10201704849PA (en)	2012-02-09	2017-07-28	Chugai Pharmaceutical Co Ltd	Modified fc region of antibody
EP2812357B1 (en)	2012-02-10	2020-11-04	F.Hoffmann-La Roche Ag	Single-chain antibodies and other heteromultimers
CN104125852B9 (zh)	2012-02-15	2017-05-17	弗·哈夫曼-拉罗切有限公司	基于Fc‑受体的亲和色谱
CA2865158C (en)	2012-02-24	2022-11-01	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
DK2857419T3 (da)	2012-05-30	2021-03-29	Chugai Pharmaceutical Co Ltd	Antigen-bindende molekyle til eliminering af aggregerede antigener
CN107964042B (zh)	2012-05-30	2022-04-19	中外制药株式会社	靶组织特异性抗原结合分子
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
KR20150030744A (ko)	2012-06-27	2015-03-20	에프. 호프만-라 로슈 아게	표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
EP3632462A1 (en) *	2012-07-06	2020-04-08	Genmab B.V.	Dimeric protein with triple mutations
BR112015000167B1 (pt) *	2012-07-06	2021-11-23	Genmab B.V.	Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
SMT202100621T1 (it)	2012-07-13	2022-01-10	Roche Glycart Ag	Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
JP6774164B2 (ja)	2012-08-24	2020-10-21	中外製薬株式会社	マウスＦｃγＲＩＩ特異的Ｆｃ抗体
AU2013306700B2 (en)	2012-08-24	2019-05-02	Chugai Seiyaku Kabushiki Kaisha	FcgammaRIIb-specific Fc region variant
KR102249779B1 (ko)	2012-12-27	2021-05-07	추가이 세이야쿠 가부시키가이샤	헤테로이량화 폴리펩티드
EA201500741A1 (ru) *	2013-01-10	2016-01-29	Генмаб Б.В.	ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
EP3611180B1 (en) *	2013-03-15	2021-12-22	Biomolecular Holdings LLC	Hybrid immunoglobulin containing non-peptidyl linkage
WO2014163101A1 (ja)	2013-04-02	2014-10-09	中外製薬株式会社	Ｆｃ領域改変体
CN118561989A (zh) *	2013-04-29	2024-08-30	豪夫迈·罗氏有限公司	Fc-受体结合的修饰的非对称抗体及使用方法
HK1213578A1 (zh) *	2013-04-29	2016-07-08	豪夫迈‧罗氏有限公司	结合人fcrn的修饰的抗体和使用方法
KR20160044060A (ko)	2013-10-11	2016-04-22	에프. 호프만-라 로슈 아게	다중특이적 도메인 교환된 통상의 가변 경쇄 항체
CN105916880B (zh)	2014-01-15	2020-01-17	豪夫迈·罗氏有限公司	具有改善的蛋白A结合作用的Fc区变体
NZ631007A (en)	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
SG10201807877TA (en)	2014-03-14	2018-10-30	Daniel Capon	Hybrid immunoglobulin containing non-peptidyl linkage
CN106103478B (zh)	2014-03-21	2020-04-03	豪夫迈·罗氏有限公司	抗体体内半寿期的体外预测
HRP20231139T1 (hr)	2014-05-06	2024-01-05	F. Hoffmann - La Roche Ag	Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
RU2714116C2 (ru)	2014-11-06	2020-02-11	Ф. Хоффманн-Ля Рош Аг	ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP6721590B2 (ja)	2014-12-03	2020-07-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性抗体
JP6227191B1 (ja)	2014-12-19	2017-11-08	中外製薬株式会社	抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
CN114773470A (zh)	2015-02-05	2022-07-22	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
FR3034420A1 (fr)	2015-03-31	2016-10-07	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-cd303
SG10201707267RA (en)	2015-12-18	2017-10-30	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
EP3397276A4 (en)	2015-12-30	2019-12-18	Kodiak Sciences Inc.	ANTIBODIES AND CONJUGATES THEREOF
JP7041634B2 (ja)	2016-03-14	2022-03-24	ビオテスト・アクチエンゲゼルシャフト	重症市中肺炎の処置
EP4659813A2 (en) *	2016-03-14	2025-12-10	Universitetet I Oslo	Engineered immunoglobulins with altered fcrn binding
EP3463461A4 (en)	2016-05-27	2020-05-20	Alexion Pharmaceuticals, Inc.	Methods for treatment of refractory generalized myasthenia gravis
MX2018014375A (es)	2016-06-17	2019-04-22	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina y metodos de uso.
CA3030099A1 (en)	2016-07-08	2018-01-11	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
BR112019001989A2 (pt) *	2016-08-02	2019-08-20	Visterra, Inc.	polipeptídeos projetados e usos dos mesmos
IL264626B (en)	2016-08-05	2022-07-01	Chugai Pharmaceutical Co Ltd	Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
ES2902670T3 (es) *	2017-01-13	2022-03-29	Taizhou Hanzhong Biopharmaceutics Inc	Anticuerpo monoclonal contra PD-1 y aplicaciones del mismo
JP2020517242A (ja)	2017-04-21	2020-06-18	スターテン・バイオテクノロジー・ベー・フェー	抗ＡｐｏＣ３抗体およびその使用方法
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
CN107748259A (zh) *	2017-07-26	2018-03-02	东曜药业有限公司	一种FcRn受体的ELISA检测方法
KR102576012B1 (ko)	2017-07-27	2023-09-07	알렉시온 파마슈티칼스, 인코포레이티드	고농도 항-c5 항체 제형
KR20200070355A (ko)	2017-10-26	2020-06-17	알렉시온 파마슈티칼스, 인코포레이티드	발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
US10538583B2 (en)	2017-10-31	2020-01-21	Staten Biotechnology B.V.	Anti-APOC3 antibodies and compositions thereof
AU2018361957B2 (en)	2017-10-31	2023-05-25	Staten Biotechnology B.V.	Anti-ApoC3 antibodies and methods of use thereof
CN111556895B (zh)	2017-11-14	2024-09-13	中外制药株式会社	抗-c1s抗体及使用方法
EP3498293A1 (en)	2017-12-15	2019-06-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Treatment of monogenic diseases with an anti-cd45rc antibody
FR3076294B1 (fr)	2017-12-29	2022-01-28	Lab Francais Du Fractionnement	Procede de purification d'anticorps a partir de lait brut
CN108101992B (zh) *	2017-12-31	2021-03-26	武汉班科生物技术股份有限公司	与新生的Fc受体结合增强的CH2结构域突变体及其制备方法与应用
JP2018138022A (ja) *	2018-02-23	2018-09-06	ゲンマブビー．ブイ．	ヒトＩｇＧ１Ｆｃ領域変異体およびその使用
KR20200140817A (ko)	2018-03-02	2020-12-16	코디악 사이언시스 인코포레이티드	Il-6 항체 그리고 이의 융합 작제물 및 접합체
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
CN112119090B (zh)	2018-03-15	2023-01-13	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
CN108519383B (zh) *	2018-04-08	2020-08-14	上海理工大学	一种全波段生物显色实验的检测方法
ES2996257T3 (en)	2018-05-31	2025-02-12	Alexion Pharma Inc	Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
WO2019235426A1 (ja) *	2018-06-04	2019-12-12	中外製薬株式会社	細胞質内での半減期が変化した抗原結合分子
US12460012B2 (en)	2018-06-04	2025-11-04	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
CN120349426A (zh)	2018-06-22	2025-07-22	科优基因公司	白介素-2变体及其使用方法
US12312394B2 (en)	2018-06-28	2025-05-27	Alexion Pharmaceuticals, Inc.	Methods of producing anti-C5 antibodies
EP3835321A4 (en)	2018-08-10	2022-11-02	Chugai Seiyaku Kabushiki Kaisha	ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
MX2021004774A (es)	2018-10-29	2021-08-24	Hoffmann La Roche	Formulacion de anticuerpos.
EA202191189A1 (ru)	2018-10-30	2021-08-06	Алексион Фармасьютикалс, Инк.	Подкожное введение и дозировка антител к c5 для лечения пароксизмальной ночной гемоглобинурии (пнг)
CN113614107A (zh)	2019-01-23	2021-11-05	Encefa公司	Cd31竞争剂及其用途
BR112021021689A2 (pt)	2019-05-15	2022-03-22	Chugai Pharmaceutical Co Ltd	Molécula de ligação a antígeno, composição farmacêutica, e método
BR112022005036A2 (pt) *	2019-09-18	2022-07-05	Momenta Pharmaceuticals Inc	Composições e métodos relacionados a construtos de domínio de ligação de antígeno-fc projetados direcionados a cd38
TW202126698A (zh)	2019-09-18	2021-07-16	美商建南德克公司	抗ｋｌｋ７抗體、抗ｋｌｋ５抗體、多重特異性抗ｋｌｋ５／ｋｌｋ７抗體、及使用方法
CN114786731A (zh)	2019-10-10	2022-07-22	科达制药股份有限公司	治疗眼部病症的方法
US11739142B2 (en)	2019-12-18	2023-08-29	Hoffmann-La Roche Inc.	Bispecific anti-CCL2 antibodies
CN113637084B (zh) *	2020-05-11	2025-08-01	上海康景生物医药科技有限公司	生物大分子靶向特异性补体抑制剂及其制备方法与应用
AU2022295067A1 (en)	2021-06-18	2023-12-21	F. Hoffmann-La Roche Ag	Bispecific anti-ccl2 antibodies
WO2024050493A2 (en) *	2022-09-02	2024-03-07	Zoetis Services Llc	Equine antibody mutants
CN121319170A (zh) *	2024-07-12	2026-01-13	菲鹏生物股份有限公司	免疫球蛋白及其用途

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4675187A (en)	1983-05-16	1987-06-23	Bristol-Myers Company	BBM-1675, a new antibiotic complex
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5047335A (en) *	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5268164A (en)	1990-04-23	1993-12-07	Alkermes, Inc.	Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en)	1990-04-23	1992-05-12	Alkermes, Inc.	Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE204902T1 (de)	1990-06-29	2001-09-15	Large Scale Biology Corp	Melaninproduktion durch transformierte mikroorganismen
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
DE69233153T2 (de)	1991-03-06	2004-05-27	Merck Patent Gmbh	Humanisierte monoklonale antikörper
US5278299A (en) *	1991-03-18	1994-01-11	Scripps Clinic And Research Foundation	Method and composition for synthesizing sialylated glycosyl compounds
US20030206899A1 (en)	1991-03-29	2003-11-06	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JP4124480B2 (ja)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
WO1993010260A1 (en) *	1991-11-21	1993-05-27	The Board Of Trustees Of The Leland Stanford Junior University	Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
DE69328430T2 (de)	1992-07-27	2001-01-25	The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer	Zielgerichte liposome zur blut-hirne schranke
JPH08500017A (ja)	1992-08-17	1996-01-09	ジェネンテク，インコーポレイテッド	二特異的免疫アドヘジン
DE69233803D1 (de)	1992-10-28	2011-03-31	Genentech Inc	Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
US5635388A (en)	1994-04-04	1997-06-03	Genentech, Inc.	Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
JPH11507535A (ja)	1995-06-07	1999-07-06	イムクローンシステムズインコーポレイテッド	腫瘍の成長を抑制する抗体および抗体フラグメント類
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
CA2249195A1 (en) *	1996-03-18	1997-09-25	Board Of Regents, The University Of Texas System	Immunoglobin-like domains with increased half lives
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
CA2273194C (en)	1996-12-03	2011-02-01	Abgenix, Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
NZ500078A (en)	1997-04-07	2001-10-26	Genentech Inc	Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
ATE501170T1 (de)	1997-04-07	2011-03-15	Genentech Inc	Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
WO1998048032A2 (en)	1997-04-21	1998-10-29	Donlar Corporation	POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
ES2244066T3 (es)	1997-06-24	2005-12-01	Genentech, Inc.	Procedimiento y composiciones de glicoproteinas galactosiladas.
US20040191256A1 (en) *	1997-06-24	2004-09-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
US6172213B1 (en) *	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en)	1997-12-05	1999-06-17	The Scripps Research Institute	Humanization of murine antibody
ATE375365T1 (de)	1998-04-02	2007-10-15	Genentech Inc	Antikörper varianten und fragmente davon
US6528624B1 (en) *	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
US6194551B1 (en) *	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
PT1071700E (pt) *	1998-04-20	2010-04-23	Glycart Biotechnology Ag	Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
ES2292682T3 (es)	1998-05-06	2008-03-16	Genentech, Inc.	Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP1141024B1 (en) *	1999-01-15	2018-08-08	Genentech, Inc.	POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US7183387B1 (en) *	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
ES2601882T5 (es) *	1999-04-09	2021-06-07	Kyowa Kirin Co Ltd	Procedimiento para controlar la actividad de una molécula inmunofuncional
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
CA2388245C (en)	1999-10-19	2012-01-10	Tatsuya Ogawa	The use of serum-free adapted rat cells for producing heterologous polypeptides
SK12232002A3 (sk)	2000-02-25	2003-03-04	The Government Of The United States, As Represented By The	Anti-ERGFRvIII scFv so zlepšenou cytotoxicitou a výťažkom, imunotoxíny a spôsoby ich použitia
US7449443B2 (en)	2000-03-23	2008-11-11	California Institute Of Technology	Method for stabilization of proteins using non-natural amino acids
JP2003531149A (ja) *	2000-04-13	2003-10-21	ザ・ロツクフエラー・ユニバーシテイ	抗体由来の免疫応答の増強
JP2003533987A (ja)	2000-05-19	2003-11-18	イスケミカルカンパニーリミテッド	表皮成長因子収容体に対するヒト化抗体
US6586207B2 (en)	2000-05-26	2003-07-01	California Institute Of Technology	Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
DE60128685T2 (de)	2000-06-23	2009-03-05	Bayer Schering Pharma Aktiengesellschaft	Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
US7598055B2 (en) *	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US6514221B2 (en)	2000-07-27	2003-02-04	Brigham And Women's Hospital, Inc.	Blood-brain barrier opening
US20020065259A1 (en)	2000-08-30	2002-05-30	Schatzberg Alan F.	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
HU231090B1 (hu)	2000-10-06	2020-07-28	Kyowa Kirin Co., Ltd.	Antitest-kompozíciót termelő sejt
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7034036B2 (en)	2000-10-30	2006-04-25	Pain Therapeutics, Inc.	Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en)	2000-11-04	2003-05-01	Ferguson Ian A.	Non-invasive delivery of polypeptides through the blood-brain barrier
US6480405B2 (en) *	2000-11-17	2002-11-12	Texas Instruments Incorporated	Full-wave rectifier
EP1355919B1 (en) *	2000-12-12	2010-11-24	MedImmune, LLC	Molecules with extended half-lives, compositions and uses thereof
CN1268394C (zh) *	2001-01-17	2006-08-09	特鲁比昂药品公司	结合域－免疫球蛋白融合蛋白
ES2364816T3 (es) *	2001-04-02	2011-09-14	Genentech, Inc.	Terapia de combinación.
DE10121982B4 (de)	2001-05-05	2008-01-24	Lts Lohmann Therapie-Systeme Ag	Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
WO2002102853A2 (en)	2001-06-14	2002-12-27	Isis Innovation Limited	Cd4-specific antibody trx1 and uses therefor
ATE445838T1 (de)	2001-07-25	2009-10-15	Raptor Pharmaceutical Inc	Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP1423510A4 (en)	2001-08-03	2005-06-01	Glycart Biotechnology Ag	ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
HUP0600342A3 (en) *	2001-10-25	2011-03-28	Genentech Inc	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
AU2003248370A1 (en)	2002-02-27	2003-09-09	California Institute Of Technology	Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US20030162695A1 (en)	2002-02-27	2003-08-28	Schatzberg Alan F.	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2481837A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Production process for antibody composition
US20050031613A1 (en)	2002-04-09	2005-02-10	Kazuyasu Nakamura	Therapeutic agent for patients having human FcgammaRIIIa
CA2481656A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
CN102911987B (zh)	2002-04-09	2015-09-30	协和发酵麒麟株式会社	基因组被修饰的细胞
WO2003085119A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
WO2003084569A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Drug containing antibody composition
SE0302312D0 (sv)	2002-10-04	2003-08-27	Forskarpatent I Syd Ab	Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2004030607A2 (en)	2002-10-04	2004-04-15	Forskarpatent I Syd Ab	Peptide-based passive immunization therapy for treatment of atherosclerosis
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003302676A1 (en)	2002-12-03	2004-06-23	Blanchette Rockefeller Neurosciences Institute	Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
DK2289936T3 (en) *	2002-12-16	2017-07-31	Genentech Inc	IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
AU2004204494B2 (en) *	2003-01-09	2011-09-29	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
PL1638941T3 (pl)	2003-05-22	2010-11-30	Abbvie Bahamas Ltd	Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz
US20050186208A1 (en) *	2003-05-30	2005-08-25	Genentech, Inc.	Treatment with anti-VEGF antibodies
WO2005044853A2 (en)	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
US20050089473A1 (en)	2003-09-10	2005-04-28	Cedars-Sinai Medical Center	Potassium channel mediated delivery of agents through the blood-brain barrier
WO2005035586A1 (ja)	2003-10-08	2005-04-21	Kyowa Hakko Kogyo Co., Ltd.	融合蛋白質組成物
SG176455A1 (en)	2003-10-09	2011-12-29	Ambrx Inc	Polymer derivatives
WO2005035778A1 (ja)	2003-10-09	2005-04-21	Kyowa Hakko Kogyo Co., Ltd.	α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
DK2380910T3 (en)	2003-11-05	2015-10-19	Roche Glycart Ag	Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	抗体組成物を含有する医薬
US7118999B2 (en) *	2004-01-16	2006-10-10	International Business Machines Corporation	Method and apparatus to increase strain effect in a transistor channel
SG135176A1 (en)	2004-02-02	2007-09-28	Ambrx Inc	Modified human four helical bundle polypeptides and their uses
US20060009360A1 (en)	2004-06-25	2006-01-12	Robert Pifer	New adjuvant composition
MX2007000404A (es) *	2004-07-12	2008-03-04	Macrogenics Inc	Identificacion de ingenieria de anticuerpos con regiones de fc variante y metodos para usar las mismas.
JP5055603B2 (ja) *	2004-08-04	2012-10-24	メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー	変異Ｆｃ領域
JP2008510466A (ja) *	2004-08-19	2008-04-10	ジェネンテック・インコーポレーテッド	エフェクター機能が変更しているポリペプチド変異体
US8367805B2 (en) *	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
AU2005304624B2 (en) *	2004-11-12	2010-10-07	Xencor, Inc.	Fc variants with altered binding to FcRn
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
RU2412200C2 (ru) *	2004-11-12	2011-02-20	Ксенкор, Инк.	Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn
EP1838735A2 (en) *	2004-12-31	2007-10-03	Genentech, Inc.	Polypeptides that bind br3 and uses thereof
CN101304791B (zh) *	2005-09-07	2010-06-16	帕尔坎Y宾公司	包括改进的三维拼板的玩具
AU2007227609A1 (en) *	2006-03-16	2007-09-27	Genentech, Inc.	Methods of treating lupus using CD4 antibodies
WO2008140603A2 (en) *	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
AR069501A1 (es)	2007-11-30	2010-01-27	Genentech Inc	Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
PL2235059T3 (pl) *	2007-12-26	2015-08-31	Xencor Inc	Warianty FC o zmodyfikowanym wiązaniu do FCRN

2009
- 2009-10-13 CN CN201910548858.4A patent/CN110317272A/zh active Pending
- 2009-10-13 BR BRPI0914091-3A patent/BRPI0914091B1/pt not_active IP Right Cessation
- 2009-10-13 PE PE2015000431A patent/PE20150682A1/es active IP Right Grant
- 2009-10-13 TW TW104123461A patent/TWI572359B/zh not_active IP Right Cessation
- 2009-10-13 ES ES09793631T patent/ES2828721T3/es active Active
- 2009-10-13 KR KR1020117010964A patent/KR101834999B1/ko not_active Expired - Fee Related
- 2009-10-13 EP EP09793631.4A patent/EP2352521B1/en active Active
- 2009-10-13 WO PCT/US2009/060443 patent/WO2010045193A1/en not_active Ceased
- 2009-10-13 KR KR1020197005957A patent/KR20190025057A/ko not_active Withdrawn
- 2009-10-13 KR KR1020187005799A patent/KR102100066B1/ko not_active Expired - Fee Related
- 2009-10-13 US US12/577,967 patent/US20100098730A1/en not_active Abandoned
- 2009-10-13 EP EP18212252.3A patent/EP3524620A1/en not_active Withdrawn
- 2009-10-13 JP JP2011531249A patent/JP5913980B2/ja not_active Expired - Fee Related
- 2009-10-13 AU AU2009303526A patent/AU2009303526B2/en not_active Ceased
- 2009-10-13 CN CN200980150204.0A patent/CN102245208B/zh not_active Expired - Fee Related
- 2009-10-13 RU RU2011119447/10A patent/RU2536937C2/ru active
- 2009-10-13 TW TW098134687A patent/TWI572357B/zh not_active IP Right Cessation
- 2009-10-13 CN CN201410562388.4A patent/CN104447990B/zh not_active Expired - Fee Related
- 2009-10-13 SG SG10201605250SA patent/SG10201605250SA/en unknown
- 2009-10-13 PE PE2011000886A patent/PE20110707A1/es active IP Right Grant
- 2009-10-13 AR ARP090103925A patent/AR073829A1/es not_active Application Discontinuation
- 2009-10-13 MX MX2011004001A patent/MX2011004001A/es active IP Right Grant
- 2009-10-13 SG SG2013076815A patent/SG195558A1/en unknown
- 2009-10-13 PL PL09793631T patent/PL2352521T3/pl unknown
- 2009-10-13 CA CA2739429A patent/CA2739429C/en active Active
2011
- 2011-03-31 IL IL212048A patent/IL212048B/en active IP Right Grant
- 2011-03-31 ZA ZA2011/02413A patent/ZA201102413B/en unknown
2014
- 2014-02-24 US US14/188,432 patent/US20140294810A1/en not_active Abandoned
2015
- 2015-01-21 CL CL2015000148A patent/CL2015000148A1/es unknown
- 2015-07-24 JP JP2015146850A patent/JP6122072B2/ja not_active Expired - Fee Related
2016
- 2016-01-12 PH PH12016500081A patent/PH12016500081A1/en unknown
2019
- 2019-01-08 IL IL264138A patent/IL264138A/en unknown
2020
- 2020-06-01 US US16/889,510 patent/US20210002359A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20190025057A (ko)	2019-03-08
ES2828721T3 (es)	2021-05-27
MX2011004001A (es)	2011-05-19
WO2010045193A1 (en)	2010-04-22
HK1163550A1 (zh)	2012-09-14
JP5913980B2 (ja)	2016-05-11
TWI572359B (zh)	2017-03-01
SG10201605250SA (en)	2016-08-30
CA2739429C (en)	2020-12-22
RU2536937C2 (ru)	2014-12-27
SG195558A1 (en)	2013-12-30
US20210002359A1 (en)	2021-01-07
US20100098730A1 (en)	2010-04-22
CN102245208A (zh)	2011-11-16
US20140294810A1 (en)	2014-10-02
PE20110707A1 (es)	2011-10-11
PL2352521T3 (pl)	2021-03-08
PE20150682A1 (es)	2015-05-20
EP3524620A1 (en)	2019-08-14
CL2015000148A1 (es)	2015-04-24
JP2012505833A (ja)	2012-03-08
EP2352521A1 (en)	2011-08-10
KR20180027609A (ko)	2018-03-14
BRPI0914091B1 (pt)	2022-05-10
PH12016500081B1 (en)	2017-01-16
TWI572357B (zh)	2017-03-01
CN110317272A (zh)	2019-10-11
AU2009303526B2 (en)	2015-01-15
AU2009303526A1 (en)	2010-04-22
CN104447990B (zh)	2019-07-19
PH12016500081A1 (en)	2017-01-16
KR102100066B1 (ko)	2020-04-10
EP2352521B1 (en)	2020-09-16
HK1209130A1 (en)	2016-03-24
AR073829A1 (es)	2010-12-01
CN104447990A (zh)	2015-03-25
JP6122072B2 (ja)	2017-04-26
JP2016026144A (ja)	2016-02-12
KR20110070914A (ko)	2011-06-24
TW201023884A (en)	2010-07-01
RU2011119447A (ru)	2012-11-27
CN102245208B (zh)	2016-03-16
CA2739429A1 (en)	2010-04-22
TW201542228A (zh)	2015-11-16
ZA201102413B (en)	2012-06-27
IL212048B (en)	2020-02-27
IL212048A0 (en)	2011-06-30
KR101834999B1 (ko)	2018-03-06
IL264138A (en)	2019-02-28

Publication	Publication Date	Title
BRPI0914091A2 (pt)	2016-09-27	"igg variante, composição farmacêutica, kit, método para tratar em tumor, método para inibir atividade de vegf, método para modular permeabilidade vascular e método para inibir ou evitar crescimento de células de câncer"
BRPI0715845A2 (pt)	2014-11-11	Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão
BRPI0813311A2 (pt)	2014-12-23	Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
IL193746A (en)	2015-05-31	Antimicrobial compositions and catheters containing the same and methods for production thereof
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BR112012018947A8 (pt)	2017-12-19	composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0812740A2 (pt)	2016-07-19	composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
WO2010034015A3 (en)	2010-07-22	Modulating the alternative complement pathway
DK1765391T3 (da)	2013-03-25	Bakterielle præparater til behandlingen af cancer
BRPI0714994A2 (pt)	2015-06-16	Sistema de tratamento de tecidos e método para controlar as informações sobre o tratamento de tecidos
BR112012018951A2 (pt)	2017-06-27	composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
EP2046315A4 (en)	2009-09-16	THERAPEUTIC AGENTS FOR THE TREATMENT OF LYMPHOID MALIGNANCIES
BR112012018943A8 (pt)	2017-12-19	medicamento e método para o tratamento e/ou prevenção de um câncer
LT1965816T (lt)	2017-07-25	Farmacinės kompozicijos ir metodai, skirti su oksalatu susijusių ligų gydymui arba prevencijai
BR112013011480A2 (pt)	2016-08-09	método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
IL185517A0 (en)	2008-01-06	Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0908635A2 (pt)	2015-10-13	composto, composição farmacêutica e método de tratamento de câncer
BRPI1009860A2 (pt)	2016-03-08	composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
BRPI0815752A2 (pt)	2015-02-18	Mimético de peptídeo tipo nap ou mimético de peptídeo tipo sal, composição farmacêutica, e, método para tratar ou prevenir doenças.
WO2007146335A3 (en)	2009-02-12	Compounds and compositions for treatment of cancer
WO2007050784A3 (en)	2007-06-14	Fixed ratio drug combination treatments for solid tumors
WO2010121164A3 (en)	2011-02-24	1,4-benzodiazepinone compounds and their use in treating cancer
BR112012002246A2 (pt)	2019-09-24	composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
BRPI0913854A2 (pt)	2016-05-17	composto, composição farmacêutica, uso do composto, e, método para o tratamento, a prevenção ou o alívio de uma doença ou um distúrbio ou uma condição de um organismo de animal vivente.
BRPI0720323A2 (pt)	2016-08-09	composto, método de tratamento, composição farmacêutica e uso do composto

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-22	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2021-07-06	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-08-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-11-23	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2022-03-15	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-05-10	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2025-09-16	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2026-01-06	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.